According to a recent LinkedIn post from Cirsium Biosciences, the company has internally developed custom “infiltrator” equipment to support its plant-based adeno-associated virus (AAV) production platform. The post describes how an initial device built in 2022 enabled manual infiltration of five plants at a time using agrobacteria-mediated gene delivery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same post indicates that Cirsium is now developing a next-generation infiltrator designed for significantly larger throughput, targeting more than 100 plants per batch with automated and tightly controlled workflows. This evolution suggests a move from proof-of-concept and small-lab operations toward more scalable, potentially pre-commercial bioprocessing infrastructure.
For investors, the emphasis on proprietary equipment and process innovation may signal an attempt to build defensible know-how and reduce reliance on off-the-shelf manufacturing tools in the emerging field of plant-based AAV production. If the new infiltrator performs as implied, it could improve capacity, reproducibility, and cost efficiency, which are critical factors for eventual partnering, clinical supply, or contract manufacturing opportunities.
More broadly, the post underscores Cirsium’s strategy of rethinking not only the biological method of producing AAV in plants, but also the supporting hardware and workflow automation. This integrated approach may enhance the company’s positioning within gene-therapy supply chains, though the financial impact will depend on validation data, regulatory progress, and the ability to translate process scale-up into sustainable revenue-generating programs or collaborations.